Cat. No. | Product name | CAS No. |
DC48401 |
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
Featured
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugate for ADC with potent antitumor activity by using TLR7/8 agonist 4, linked via the cleavable ADC linker hydroxy-PEG10-acid. |
2388520-36-1 |
DC50212 |
CL2E-SN38
CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor. |
1639139-65-3 |
DC50213 |
Aminooxy CatB-LXR
Aminooxy CatB-LXR (compound 10) is a drug-linker conjugates for ADC. |
1779524-93-4 |
DC50214 |
MC-Val-Cit-PAB-DX8951
MC-Val-Cit-PAB-DX8951 is a drug-linker conjugate for ADC. MC-Val-Cit-PAB-DX8951 is composed of a DNA topoisomerase I DX-8951 and a cathepsin cleavable ADC linker. |
2504068-28-2 |
DC50215 |
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT is a drug-linker conjugate for antibody-drug conjugate (ADC). MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT has the potential for cancer and autoimmune disease research. |
2639190-44-4 |
DC50216 |
CL2E-SN38 TFA
CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor. |
|
DC71115 |
SN38 NHS ester
Featured
SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs). |
2400904-71-2 |
DC71150 |
Aminobenzenesulfonic auristatin E
Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic. |
1800462-99-0 |
DC71664 |
Val-Cit-PAB-MMAF sodium
Featured
Val-Cit-PAB-MMAF sodium is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF. |
|
DC71665 |
Val-Cit-PAB-MMAF
Featured
Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF. |
863971-56-6 |
DC71666 |
MC-VA-PABC-MMAE
MC-VA-PABC-MMAE is a drug-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE. |
1818864-51-5 |
DC71667 |
Aminobenzenesulfonic auristatin E TFA
Aminobenzenesulfonic auristatin E TFA is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic. |
|
DC80073 |
Azido-PEG4-EV-Cit-PAB-MMAE
Featured
Azido-PEG4-EV-Cit-PAB-MMAE is a precursor of antibody drug conjugate. |
|
DC71949 |
MC-VA-PAB-Exatecan
MC-VA-PAB-Exatecan is a drug-linker conjugate for ADC. MC-VA-PAB-Exatecan contains the ADC linker (peptide MC-VA-PAB) and a DNA topoisomerase I inhibitor Exatecan. MC-VA-PAB-Exatecan synthesized ADC shows good antitumor activity. |
2680543-57-9 |
DC71950 |
Ac-Lys-Val-Cit-PABC-MMAE
Ac-Lys-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE. |
1650569-89-3 |
DC71951 |
Aminobenzenesulfonic auristatin E-d8
Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic. |
|
DC72119 |
Deruxtecan analog 2
Deruxtecan analog 2 (example 9 P3) is a Deruxtecan analog. Deruxtecan analog 2 is a drug-linker conjugate composed of Camptothecin and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC. |
1599440-10-4 |
DC72257 |
TAM558
TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470, with antitumor activity. |
1802499-21-3 |
DC72532 |
Fmoc-VAP-MMAE
Fmoc-VAP-MMAE is a drug-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE, with a protective Fmoc group. |
1912408-91-3 |
DC72533 |
ATAC21
ATAC21, a linker-immune-stimulatory compound that can be formed by conjugating a noncleavable maleimide-PEG4 linker containing a succinimide group with an immune- stimulatory compound. ATAC21 can be combined with SBT-040 (anti-CD40 antibody) to form a conjugate. |
2101204-23-1 |
DC74469 |
ZD06519
ZD06519 is a novel camptothecin payload for antibody drug conjugates (ADCs) with highp ayload potency (~1 nM). |
2873460-17-2 |
DC74470 |
SuO-Val-Cit-PAB-MMAE
Featured
A drug-linker conjugate for antibody-drug conjugate by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide SuO-Val-Cit-PAB.. |